drugset / Trial / NCT04676607
SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase 2
Completed
6 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NaSingle-groupOpen-labelTreatment
Summary
This trial aims to prospectively assess the safety and efficiency of SHR7390 in metastatic castration-resistant prostate cancer
Timeline
- Start
- 2020-12-17
- Primary completion
- 2023-06-12
- Completion
- 2023-06-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR7390 | Unknown | — | — |